EC OKs 46M euros for R&D BioIntelligence
The European Commission has cleared the way for the French government to put 46.3 million euros ($62.5 million) into the country's R&D BioIntelligence project. The program was established in 2005 under what was then the Industrial Innovation Agency (A2I), now the OSEO (Marketletters passim). Over the next five years, a total of 118.2 million euros is to be spent in this scheme.
Neelie Kroes, the European Competition Commissioner, said: "thanks to this especially innovative program, biological research will see its efficiency substantially increased by the modelling and simulation systems. BioIntelligence and the BioPLM platform it intends to develop, are at the crossroads of the leading objectives of European research, without the aid inducing any important distortions to competition."
Dassault Systemes coordinates R&D project
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze